A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
Running, not enrolling · Phase 1/Phase 2
Conditions studied: Type 1 Diabetes
In brief
The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
Key facts
- Study ID
- NCT05791201
- Run by
- Vertex Pharmaceuticals Incorporated
- People needed
- 7
- Starts
- 2023-05-16
- Expected to finish
- 2027-03-12
- Last updated by the study team
- 2026-06-04
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UHealth Diabetes Research Institute — Miami, Florida, United States
- University of Chicago — Chicago, Illinois, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
- University of Pittsburgh Medical Center Montefiore — Pittsburgh, Pennsylvania, United States
- University of Wisconsin — Madison, Wisconsin, United States
- University of Alberta, Edmonton — Edmonton, Canada
- Montreal Clinical Research Institute — Montreal, Canada
- Toronto General Hospital (TGH) — Toronto, Canada
- Vancouver General Hospital — Vancouver, Canada
- Dresden Center for Islet Transplantation — Dresden, Germany
- IRCCS Ospedale San Raffaele — Milan, Italy
- Leiden University — Leiden, Netherlands
- Hopiteaux Universitaires de Geneve — Geneva, Switzerland
- Churchill Hospital — Headington, United Kingdom
- Royal Victoria Infirmary — Newcastle upon Tyne, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.